|Bid||62.00 x 3100|
|Ask||80.00 x 2200|
|Day's Range||72.11 - 74.97|
|52 Week Range||22.36 - 93.94|
|Beta (5Y Monthly)||1.90|
|PE Ratio (TTM)||149.86|
|Earnings Date||Aug 05, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||79.89|
Denali Therapeutics (DNLI) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.